A 6 Week, Multicenter, Open-label Trial to Evaluate the Safety, Tolerability and Efficacy of Lumiracoxib 200mg o.d. in Patients With Primary Knee Osteoarthritis or Rheumatoid Arthritis.
Phase of Trial: Phase III
Latest Information Update: 18 May 2012
At a glance
- Drugs Lumiracoxib (Primary)
- Indications Osteoarthritis; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Novartis
- 05 Jun 2009 New trial record.